# A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®

> **NCT07062978** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 278 (estimated)

## Conditions studied

- Postmenopausal Women With Osteoporosis at High Risk of Fracture

## Interventions

- **DRUG:** QL1206
- **DRUG:** Prolia®

## Key facts

- **NCT ID:** NCT07062978
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 278 (ESTIMATED)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07062978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07062978, "A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07062978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*